SigrunHallmeyerMD

Chair, Cancer Committee, Advocate Lutheran General Hospital. Member, Division of Hematology/Oncology, Lutheran General Hospital. Oncology Specialists at Oncology Specialists, S.C.

Join to view full profile

Dr. Hallmeyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hallmeyer's full profile

Already have an account?

Office
1700 Luther Ln
Fl 2
Park Ridge, IL 60068
Phone+1 847-268-8200

Fax+1 847-318-2905

Education & Training

University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 2002 - 2005
UPMC Medical Education (Harrisburg)Residency, Internal Medicine, 1999 - 2002
Humboldt University of Berlin - Charite Faculty of MedicineClass of 1998

Certifications & Licensure

IL State Medical License 2002 - 2026
PA State Medical License 2000 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
Active, not recruiting
Phase 3
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Effectiveness of the Advocate Lutheran General Survivorship Center Programs Start of enrollment: 2016 Oct 01
Completed
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members Start of enrollment: 2020 Aug 26
Completed
Join now to see all

Publications & Presentations

PubMed

4 citations
Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
Ilana M Braun, Kari Bohlke, Donald I Abrams, Holly Anderson, Lynda G Balneaves
Journal of Clinical Oncology. 2024-05-01
1 citations
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.
John M Kirkwood, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang
Immunotherapy. 2024-01-01
1 citations
Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing.
Sigrun Hallmeyer, Michael A Thompson, Veronica Fitzpatrick, Yunqi Liao, Michael P Mullane
Biology Methods & Protocols. 2023-01-01

Press Mentions

Local Breast Cancer Trials Testing Effectiveness of Less Toxic TreatmentsOctober 24th, 2024
Young Lymphoma Patients Face More Health Woes down the Line. Advocate Wants to Know WhyAugust 16th, 2024
Compass Trial: A New Way to Approach Breast CancerNovember 22nd, 2022
Join now to see all